AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Phase 1 clinical trial of onCARlytics has moved to the combination arm based on the recommendation of the Cohort Review Committee (CRC).
- No safety issues were reported in the monotherapy arm of the trial.
- In the combination arm, onCARlytics will be paired with the CD19 targeting drug blinatumomab.
Imugene Limited (ASX: IMU) has shared positive updates on its Phase 1 onCARlytics (on-CAR-19, CF33-CD19 HOV4) solid tumour trial.
The company has successfully completed the initial cohort within the intratumoural monotherapy arm, prompting preparations to commence combination dosing of the CD19-targeting drug blinatumomab with onCARlytics in solid tumour patients.
About the trial
The OASIS trial is a pioneering study designed to analyse the efficacy and safety profile using two administration routes in adult patients with metastatic or advanced solid tumours. The routes include intravenous (IV) infusion and intratumoural (IT) injection, assessed independently or in conjunction with blinatumomab.
This dose escalation study will be conducted across multiple sites in the United States, with an expected enrolment of 52 patients.
The title of the trial is -
Data source: Company update
About the combination arm of the study
The company has opened the combination arm of the trial following the recommendation from the Cohort Review Committee (CRC). The committee reported no safety issues in the monotherapy arm of onCARlytics solid tumour trial.
To date, in the monotherapy arm, patients with ovarian, melanoma and breast cancers have been treated.
The combination arm involves the pairing of onCARlytics with CD19 targeting drug blinatumomab.
While blinatumomab, marketed as Blincyto® by Amgen, cannot treat solid tumours alone, onCARlytics has demonstrated the potential to eradicate and target solid tumours.
IMU shares jumped over 2% to trade at AU$0.112 apiece at the time of writing on 11 March 2024.